You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Patent: 9,375,434

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,375,434
Title:Antitumor effect potentiator composed of imidazooxazine compound
Abstract: An antitumor effect potentiator for potentiating one or more other antitumor agents, comprising, as an active ingredient, an imidazooxazine compound represented by Formula (I), or a pharmaceutically acceptable salt thereof, ##STR00001## wherein A, B, C, and D represent C--R.sup.1a, C--R.sup.1b, C--R.sup.1c, and C--R.sup.1d, respectively, or one or two of A, B, C, and D represent an N atom; at least two of R.sup.1a, R.sup.1b, R.sup.1c, and R.sup.1d represent hydrogen, and the other(s) represent(s) halogen; cyano; C.sub.1-6 alkyl that may have hydroxyl group(s) as substituent(s); C.sub.1-6 alkoxy; carbonyl having, as a substituent, hydroxyl, amino, optionally substituted mono- or di-(C.sub.1-6 alkyl)amino, or mono- or di-(C.sub.1-6 alkoxy)amino; or an unsaturated heterocyclic group; R.sup.2 represents phenyl, pyridyl, or thienyl; R.sup.3 represents hydrogen, methyl, ethyl, or cyclopropyl; and R.sup.4 represents hydrogen or hydroxy.
Inventor(s): Ichikawa; Koji (Tsukuba, JP), Okada; Megumu (Tsukuba, JP)
Assignee: Taiho Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:14/407,745
Patent Claims:see list of patent claims

Details for Patent 9,375,434

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Taiho Pharmaceutical Co., Ltd. (Tokyo, JP) 2032-07-02 RX Orphan search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Taiho Pharmaceutical Co., Ltd. (Tokyo, JP) 2032-07-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.